Proactive Investors - Run By Investors For Investors

Allergy Therapeutics hails progression of peanut allergy vaccine

Allergy Therapeutics (LON:AGY) international medical director Dr Matthias Kramer talks to Proactive about the company taking its Polyvac vaccine for peanut allergy into a phase I clinical trial after it delivered positive pre-clinical results.

The company is developing Polyvac as a short course of injections that is safer and more effective than the current treatments.

Meet Tower Resources PLC, Arc Minerals Limited, Carbon Tracker, Tekcapital PLC and Serinus Energy at our event, London , 31 May 2018. Register here »
View full AGY profile View Profile

Allergy Therapeutics plc Timeline

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use